The use of COLD-PCR and pyrosequencing for sensitive detection of EGFR T790M mutation
-
Published:2021
Issue:
Volume:271
Page:03026
-
ISSN:2267-1242
-
Container-title:E3S Web of Conferences
-
language:
-
Short-container-title:E3S Web Conf.
Author:
Chen Huimin,Zhang Yang,Pu Dan,Shu Kunxian
Abstract
A sensitive and convenient method for the detection of epidermal growth factor receptor (EGFR) T790M mutation in non-small cell lung cancer (NSCLC) patients with acquired resistance to tyrosine kinase inhibitors (TKIs) would be desirable to guide treatment strategy. Consequently, studies have focused on sensitive characterization of EGFR T790M mutation. Herein, two methods of co-amplification at lower denaturation temperature PCR (COLD-PCR) and pyrosequencing were combined (COLDPCR/ pyrosequencing) for detecting EGFR T790M mutation. Evaluation of mutation-containing dilutions revealed that the sensitivities of COLD-PCR/pyrosequencing and conventional PCR/pyrosequencing assays for the detection of the T790M mutation were 0.1 and 5%, respectively, indicating a 50-fold increase in sensitivity. When the T790M mutation in 20 clinical NSCLC samples who had relapsed under firstgeneration EGFR TKI were further determined using COLD-PCR/pyrosequencing and conventional PCR/pyrosequencing, the detection rates were 35% (7/20) and 25% (5/20), respectively. All patients who were positive for the T790M mutation with conventional PCR/pyrosequencing were also found to be positive with COLD-PCR/pyrosequencing. The discordant cases were 2 samples with no T790M mutation detected with conventional PCR/pyrosequencing, but which were positive with COLD-PCR/pyrosequencing. COLD-PCR/pyrosequencing is a sensitive and cost-effective tool for detecting the T790M mutation which will permit an improvement of therapeutic management.
Reference24 articles.
1. Wang W., Song Z., Zhang Y., Cancer medicine 6, 154–162 (2017). 2. Rosell R., Bivona T. G., Karachaliou N., Lancet 382, 720–731 (2013). 3. Oxnard G. R., Arcila M. E., Sima C. S., Riely G. J., Chmielecki J., Kris M. G., Pao W., Ladanyi M., Miller V. A., Clin Cancer Res 17, 1616–1622 (2011). 4. Wu Y. L., Tong R. Z., Zhang Y., Hu B. B., Zheng K., Ding Z. Y., Peng F., Gong Y. L., Liu Y. M., Lu Y., Oncotargets Ther 10, 3307–3312 (2017). 5. Lettig L., Sahnane N., Pepe F., Cerutti R., Albeni C., Franzi F., Veronesi G., Ogliari F., Pastore A., Tuzi A., Pinotti G., Bovio A., Verusio C., Giordano M., Troncone G., Sessa F., Malapelle U., Furlan D., Transl Lung Cancer R 8, 584 (2019).
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|